3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
80
Breast Neoplasms
52
Prostatic Neoplasms
42
Lung Neoplasms
29
Multiple Myeloma
28
Parkinson Disease 4, Autosomal Dominant Lewy Body
22
Neoplasms
21
Neoplasm Metastasis
20
Leukemia, Lymphocytic, Chronic, B-Cell
19
Colorectal Neoplasms
19
Carcinoma, Renal Cell
19
Ovarian Neoplasms
17
Squamous Cell Carcinoma of Head and Neck
13
Recurrence
12
Leukemia, Myeloid, Acute
12
Urinary Bladder Neoplasms
11
Small Cell Lung Carcinoma
11
Pancreatic Neoplasms
11
Myasthenia Gravis
11
Endometrial Neoplasms
11
Triple Negative Breast Neoplasms
10
Stomach Neoplasms
9
Non-Muscle Invasive Bladder Neoplasms
9
Nasopharyngeal Carcinoma
9
Lymphoma, Large B-Cell, Diffuse
9
Fallopian Tube Neoplasms
9
Lymphoma, Non-Hodgkin
8
Lymphoma, Follicular
8
Carcinoma
8
Burkitt Lymphoma
8
Interventions
pembrolizumab
1
Pemetrexed
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Pathologic Processes
×
30 days
×
Clear all
NCT06119581
2026-05-19
SUNRAY-01
Eli Lilly and Company
Phase 3
Recruiting
1,264 enrolled